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Abstract
Introduction and aim: The popularity of complementary and alternative medicine (CAM) in treating functional gastrointes-
tinal disorders (FGIDs) has steadily increased in Western countries. We aimed at analyzing available data on CAM effect-
iveness in functional dyspepsia (FD) patients.
Methods: A bibliographical search was performed in PubMed using the following keywords: ‘‘complementary/alternative
medicine,’’ ‘‘hypnosis,’’ ‘‘acupuncture’’ and/or ‘‘functional dyspepsia.’’
Results: In community settings, almost 50% of patients with FGIDs used CAM therapies. Herbal remedies consist of
multi-component preparations, whose mechanisms of action have not been systematically clarified. Few studies analyzed
the effectiveness of acupuncture in Western countries, yielding conflicting results and possibly reflecting a population bias of
this treatment. Hypnosis has been extensively used in irritable bowel syndrome, but few data support its role in treating FD.
Conclusions: Although some supporting well-designed studies have been recently performed, additional randomized,
controlled trials are needed before stating any recommendation on CAM effectiveness in treating FD.
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Introduction
Patients’ requests for a ‘‘holistic’’ treatment to func-
tional gastrointestinal disorders (FGID) have been
steadily increasing in recent years.1 Nonetheless, this
approach is often dismissed by physicians, based on
the perception of a lack of scientiﬁc back-up to com-
plementary and alternative treatment (CAM).2 The
available literature on CAM has been historically lim-
ited by a poor research approach in terms of sample
size, randomization, outcome parameters and statistical
evaluation.1,2 However, a number of randomized,
controlled trials (RCTs) have recently provided sound
evidence of CAM eﬀectiveness in FGIDs.3 CAM is
broadly deﬁned as ‘‘Medical practices neither taught
widely in medical schools nor generally available in
public hospitals’’4 (Figure 1). Recent United States
(US) reports suggest that CAM therapies to treat GI
disorders have been increasingly employed all over the
world.4 In a Canadian community setting, almost 50%
of gastroenterology outpatients were found to imple-
ment treatments with supportive CAM therapies.5
More recently, a multicenter study of 199 FGID
patients found that 64% were using diet/herbal reme-
dies and 49% CAM as supportive treatment options.6
Women and whites tend to use CAM more than men
and African Americans do, respectively.6 Higher levels
of education, higher annual incomes and comorbid
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medical conditions also correlate with CAM usage.4,6
This information might be useful to gastroenterologists
to determine which patients are likely to use these
therapies. Regardless of the therapies employed,
CAM modality is intended by patients to restore bal-
ance and to facilitate the body’s own healing responses,
thereby ameliorating troublesome symptoms.6
According to the Rome IV criteria, functional
dyspepsia (FD) refers to a heterogeneous group of
symptoms arising from the epigastric region in the
absence of organic disease that are likely to explain
the symptoms.7 FD pathophysiology is still uncertain
but seems to be related to multiple mechanisms8 and
despite current guidelines, the treatment of FD remains
unsatisfactory.7,8 Studies suggest that patients often
look for person-centered care and personal physician-
patient interactions. This search for a ‘‘holistic’’
approach might explain patients’ choice to implement
prescription treatment with CAM in FD.1 This review
will focus on the eﬃcacy, safety and clinical data of
CAM in FD to improve the physician approach to
this appealing therapeutic option. Consideration is
mostly limited to randomized or quasi-randomized
trials to avoid emphasizing the magical allure still
clouding some CAM approaches.
Herbal supplements
An overview of the herbal supplements’ trial is sum-
marized in Table 1. Most of these herbal supplements
are multi-component preparations with a wide variety
of eﬀects on GI function that have not been fully clar-
iﬁed so far.9 The supposed inhibition of smooth muscle
contractility has provided the rationale to study
the eﬃcacy of peppermint oil (Mentha piperita) and
caraway oil (Carum carvi), as single supplements or in
combination.10,11 Also, an allosteric eﬀect of menthol
and peppermint oil on the 5-HT 3 receptor has been
proposed to explain its antiemetic action; however,
the eﬀect was weak and may not be clinically relevant.12
Furthermore, peppermint oil has been used tradition-
ally in the management of gallstones, as a choleretic
action of the oil has been described.13 Finally, pepper-
mint oil seemed also to exert a signiﬁcant spasmolytic
eﬀect in the esophagus, lower stomach and duodenal
bulb when orally administered in dyspepsia patients
prior to barium meal and follow-through.14 In several
trials, peppermint and caraway oil were found to be
more eﬀective than placebo in improving dyspeptic
symptoms.3,15 In the most recent RCT, 96 FD patients
were treated with either a ﬁxed combination of pepper-
mint oil and caraway oil (PCC; Enteroplant) or placebo
for four weeks. The average intensity of epigastric pain
was decreased by 40% in the herbal group compared to
22% of the placebo recipients.15 Capsaicin has been
traditionally used to treat various pain syndromes for
its ability of selectively impair the action of nociceptive
ﬁbers.16–18 Red pepper powder (Capsicum annuum) was
more eﬀective than placebo in improving dyspeptic
symptoms in a small-sized (30 participants) RCT. The
authors speculated a potential action on gastric visceral
nociception, but no additional studies have replicated
these data. Ginger (Zingiber oﬃcinale) has been trad-
itionally used to treat dyspepsia.19,20 Recently, the
eﬀect of ginger on gastric sensorimotor function was
investigated in 11 FD patients. In this small-sized
open study, ginger displayed prokinetic eﬀects, but
had no impact on gastric sensation, dyspeptic symp-
toms or gut peptides/hormones.21 Artichoke (Cynara
scolymus) leaf extracts have been commonly used to
treat dyspeptic symptoms as its bitter compounds
(cynaropicrin) are believed to increase bile ﬂow exerting
hepatoprotective, antioxidant and antispasmodic
eﬀects.22–24 In a multicenter, double-blind RCT, 247
FD patients were treated with either a commercial arti-
choke leaf extract (ALE) preparation or placebo. After
six weeks, the ALE preparation was signiﬁcantly more
eﬀective, by intention-to-treat analysis, than placebo in
alleviating symptoms (p< 0.001) and improving quality
of life (QoL) index in FD patients. Interestingly,
patients reporting symptom improvement on ALE
observed it since the ﬁrst week of therapy.25 Finally,
the best investigated herbal supplement to treat func-
tional dyspepsia is STW5, known as Iberogast, a com-
bination of herbal supplements empirically used in
treating GI symptoms in German-speaking countries.
Iberogast is an alcoholic extract of nine herbal supple-
ments whose proposed mechanism of action is to
modulate most of the potential alterations underlying
FD. Four studies evaluated STW5 versus placebo and
one study tested the non-inferiority of STW5 over the
prokinetic drug cisapride. Von Arnim et al. performed
Definition of complementary medicine adopted by the
cochrane collaboration
˝Complementary and alternative medicine (CAM) is a 
broad domain of healing resources that encompasses
all health systems, modalities, and practices and their
accompanying theories and beliefs, other than those
intrinsic to the politically dominant health system of a 
particular society or culture in a given historical period.
CAM includes all such practices and ideas self-defined
by their users as preventing or treating illness or
promoting health and well-being. Boundaries within
CAM and between the CAM domain and that of the 
dominant system are not always sharp or fixed.˝(5)
Figure 1. Definition of complementary and alternative medicine
(CAM) therapy according to the Cochrane Collaboration.
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a double-blind, placebo-controlled RCT on 315 FD
patients (Rome II criteria).26 After seven days of wash-
out, the patients were randomized to an eight-week
treatment with either STW5 or placebo.26 After four
and eight weeks of treatment, the improvement in GI
symptom score (GIS) was signiﬁcantly higher in the
STW5 group compared to placebo (p< 0.05). As sec-
ondary outcome measures, investigators’ and patients’
global symptom assessments conﬁrmed the superiority
of STW5 over placebo. At follow-up consultation,
patients treated with STW5 remained recurrence free
longer than patients who had received placebo. The
overall tolerability of STW5 and placebo were compar-
able, though ﬁve patients reported adverse events
potentially related to STW5 (abdominal pain, pruritus,
sore throat, alopecia, hypersensitivity, hypertension, GI
pain). The other three studies, two published in
German,27–29 replicated the data of a statistically
signiﬁcant superiority of STW5 versus placebo.
One of these studies considered gastric emptying as a
secondary outcome in patients with dyspepsia and gas-
troparesis.30 However, no relationship between symp-
tom improvement and acceleration of gastric emptying
could be demonstrated. Furthermore, a double-blind,
non-inferiority RCT had compared STW5 to cisapride
in 186 FD patients showing analog eﬀectiveness for
both medications.30 The eﬀectiveness of Iberogast has
also been conﬁrmed by meta-analyses, the most recent
of which included up to 637 patients showing a stan-
dardized mean diﬀerence of 1.1 over placebo,
although there was statistically signiﬁcant heterogeneity
between studies.31–34
Traditional Chinese and Japanese medicine have
been used for centuries to treat a number of symptoms,
but only recently, the Kampo therapy has been system-
atically evaluated.35 The ailment most studied is the
rikkunshito treatment, which has been studied in
Japanese scientiﬁc literature since 1500.36 Rikkunshito
is a complex herbal remedy composed of eight constitu-
ents. However, recent deeper chromatographic analysis
showed that the rikkunshito formula was even more
complex, revealing several additional ingredients.35 In
animal models, rikkunshito seems to accelerate gastric
emptying by increasing ghrelin plasma concentration,
but human studies are inconclusive.36–39 However, a
barostat study researching gastric response to environ-
mental stress showed that rikkunshito improved gastric
volume thresholds for generation of ﬁrst sensation and
epigastric discomfort, suggesting a potential modula-
tion of visceral aﬀerents.38 A recent multicenter RCT
has been run in Asia on 247 FD patients (Rome III) to
compare the eﬃcacy of rikkunshito or placebo for eight
weeks.36–40 Symptomatic improvement was recorded,
as well as plasma ghrelin levels before and after
treatment. Approximately one-third of patients in the
rikkunshito group met the primary aim, without reach-
ing statistical signiﬁcance versus placebo (p¼ 0.09).
On the contrary, epigastric pain was signiﬁcantly
improved by rikkunshito treatment compared to pla-
cebo while other dyspeptic symptoms and ghrelin con-
centration were not aﬀected.38,39
Acupuncture
Acupuncture has been used to treat FD in Eastern
countries for several millennia, although the underlying
mechanism remains unclear. The practice of acupunc-
ture consists of inserting ﬁne, solid needles (32 to 36
gauge) into selected body locations (acupoints). More
than 300 points located in systematic fashion on merid-
ians or channels of energy ﬂow are mapped onto the
body surface. Key principles in traditional Chinese
medicine are that both wellness and illness result from
an imbalance of yin (the feminine aspect of life) and
yang (its male counterpart). The movement between
these opposite forces, named Qi, is considered to be
the essential element in the healing system. In
Western countries, acupuncture is being increasingly
accepted as an alternative treatment for FGIDs.41,42
Ma et al. have conducted an RCT to assess the eﬃcacy
of acupuncture in FD compared to Itopride.43 In this
trial, 712 FD patients were randomly assigned to
receive acupuncture at speciﬁc and non-speciﬁc acu-
points versus sham acupuncture and a drug control
group for four weeks. Treatment eﬃcacy was evaluated
at the end of treatment and at 12 weeks’ follow-up con-
sultation. All groups had an improvement both in
symptoms and QoL scores at the end of treatment
that was sustained for the whole follow-up. The overall
response rate was signiﬁcantly higher in the acupunc-
ture group on speciﬁc acupoints (70.69%) than in the
other groups with the lowest response observed in the
sham acupuncture group (34.75%). Also, the QoL
scores improved signiﬁcantly in the speciﬁc acupunc-
ture group. These results showed that acupuncture at
speciﬁc points of the stomach meridian was superior to
acupuncture at points of other meridians and sham
points, as well as oral administration of Itopride.
These data have been recently replicated in a small-
sized study evaluating 30 FD patients treated according
to a cross-over design by acupuncture at speciﬁc points,
acupuncture at non-speciﬁc points and standard care.44
Recently, Zeng et al. studied brain responses to acu-
puncture in FD.45 Seventy-two FD patients were ran-
domly assigned to receive either sham or classic
acupuncture on four speciﬁc acupoints: ST34
(Liangqiu), ST36 (Zusanli), ST40 (Fenglong), and
ST42 (Chongyang) (see Figure 2). Ten patients in each
group were randomly selected for ﬂuorine-18 ﬂuoro-
deoxyglucose positron emission tomography-computed
8 United European Gastroenterology Journal 6(1)
tomography (PET-CT) scans to detect cerebral glyco-
metabolism changes. Neuroimaging indicated that the
acupuncture group showed extensive deactivation in
cerebral activities compared with the sham acupuncture
group. This deactivation was associated with symptom
improvement, suggesting the potential eﬀectiveness of
acupuncture at speciﬁc points in FD.45 This assumption
has been partially supported by a recent PET-CT scan
study investigating similarities and diﬀerences in clin-
ical and cerebral responses at diﬀerent acupoints in 20
FD patients.46 In this study, diﬀerent acupoints showed
similar clinical eﬃcacy but relatively diﬀerent cerebral
responses. The authors speculated that the inﬂuence on
the sensory transduction regions and visceral modula-
tion regions might be the common mechanism of
diﬀerent acupoint treatment.46 Nevertheless, a
Cochrane review concluded that ‘‘It remains unknown
whether manual acupuncture or electroacupuncture
is more eﬀective or safer than other treatments’’ in
FD patients.47 More recently, a meta-analysis
including almost the same studies as the Cochrane’s
review reached opposite conclusions stating that
‘‘Acupuncture appears to be eﬃcacious in relieving
FD symptoms and improving quality of life.’’48
It should be acknowledged that the few studies run in
Western countries did not provide positive outcome
data, reinforcing the population bias of this intriguing
treatment.47,48
Hypnosis
Hypnosis can be deﬁned as an altered state of
consciousness, diﬀerent both from sleep and normal
wakefulness, characterized by highly focused attention
and heightened compliance with suggestion.49 Clinical
hypnosis relies on deliberately inducing the state of
hypnosis in a patient through verbal guidance, and
making use of its properties for targeted therapeutic
purposes. Hypnotherapy delivered as a structured,
multi-session, focused intervention has been extensively
used to treat irritable bowel syndrome according to the
gut-focused protocols of the Manchester or the North
Carolina group.50 Recently, the Manchester group has
also provided experimental evidence to support the use
of hypnotherapy in FD. Calvert et al.50 randomized 126
FD patients to hypnosis, supportive therapy plus pla-
cebo medication, or medical treatment (ranitidine
300mg/day) for 16 weeks. Change in symptoms from
baseline was assessed both short term (16 weeks) and
long term (56 weeks). QoL was also measured as a
secondary outcome. Hypnosis was induced using eye
ﬁxation followed by progressive muscular relaxation
and deepened by standard procedures. Suggestions of
improvement in gastric motor function, sensitivity and
gut secretion activity were also given. At the short-term
follow-up, hypnotherapy was signiﬁcantly more eﬀect-
ive than both the supportive and the medical treatment
in ameliorating symptoms and QoL scores, even at
long-term follow-up. In addition, general practitioner
consultations for dyspeptic symptoms were dramatic-
ally decreased. The authors concluded that hypnother-
apy is both an eﬀective and cost-eﬀective treatment for
FD, but the mechanism(s) of action remained
speculative.50
Chiarioni et al.51 studied gastric emptying by ultra-
sonography and epigastric sensations in 11 healthy
individuals and in 15 FD patients under three condi-
tions: (a) basal, (b) after cisapride 10mg and (c) during
90 minutes of a gut-oriented hypnotic trance. Eight
healthy individuals repeated an emptying study listen-
ing to relaxing music. Hypnosis was signiﬁcantly more
eﬀective than cisapride and relaxing music in decreasing
gastric emptying duration both in dyspeptics and
healthy volunteers (p< 0.005). Symptoms were signiﬁ-
cantly improved by hypnosis in FD patients, but no cor-
relation with gastric emptying time could be found.
Liangqiu
Fenglong
Zusanli
Chongyang
Figure 2. A schematic representation of the four classic acu-
puncture points for gastric disorders: ST34 (Liangqiu), ST36
(Zusanli), ST40 (Fenglong) and ST42 (Chongyang).
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Therefore, a single session of hypnosis is as eﬀective as
prokinetic treatment in FD, but the mechanism under-
lying symptom improvement remains unclear. One can
speculate that since FD pathophysiology is multifactor-
ial and involves many components of the brain/gut
axis, hypnosis might target diﬀerent pathophysiological
mechanisms in FD. The state of profound relaxation
achieved during hypnosis is associated with a sustained
and generalized reduction of the sympathetic activity,
lasting even after the actual hypnosis interval.
Furthermore, hypnosis might decrease visceral hyper-
sensitivity, a hallmark feature of all functional
syndromes. Brain imaging studies in FD are consistent
with a disproportionate activation of the anterior
cingulated cortex, responsible for the aﬀective response
to pain. Hypnosis has been shown to decrease reported
pain sensation in response to painful stimuli, by likely
reducing the activity of the anterior cingulated cortex.49
Although these conceptual premises imply that
hypnotherapy might represent an appealing therapeutic
option, dedicated expertise is a must and additional
RCTs in FD are needed before stating
recommendation.51,52
Conclusions
CAM therapies oﬀer the potential to be considered in
alternate and mainstream treatment of FD. An increas-
ing body of literature provides sound evidence of eﬀect-
iveness of herbal supplements in FD, although
supporting well-designed studies aimed at identifying
the active components, the potential receptors and the
mechanism of action involved in symptom relief are
needed. However, the overriding lesson seems to be
that the clinical eﬃcacy of these multi-component prep-
arations relies on a multi-targeted approach to multifac-
torial disorders. Acupuncture is a traditionally accepted
therapy in Asia, but its use in Western countries is far
from being considered by the general population for the
lack of scientiﬁc background. In the future, hypnosis
might be an appealing treatment option, but studies
supporting its therapeutic eﬃcacy are eagerly awaited.
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